Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD
Moein Ala
Endocrinology (2021) Vol. 162, Iss. 12
Open Access | Times Cited: 46

Showing 26-50 of 46 citing articles:

Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders.
Habib Yaribeygi, Mina Maleki, Tannaz Jamialahmadi, et al.
PubMed (2023) Vol. 22, pp. 403-414
Closed Access | Times Cited: 6
A revisit of drugs and potential therapeutic targets against non-alcoholic fatty liver disease: learning from clinical trials
Shenglong Zhu, Zhiming Wu, Wenxin Wang, et al.
Journal of Endocrinological Investigation (2023) Vol. 47, Iss. 4, pp. 761-776
Closed Access | Times Cited: 6
Hyponatremia-related liver steatofibrosis and impaired spermatogenesis: evidence from a mouse model of the syndrome of inappropriate antidiuresis
Giada Marroncini, Cecilia Anceschi, Laura Naldi, et al.
Journal of Endocrinological Investigation (2022) Vol. 46, Iss. 5, pp. 967-983
Open Access | Times Cited: 8
MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development
Farah Khaznadar, Omar Khaznadar, Ana G. Petrovic, et al.
(2024)
Open Access | Times Cited: 1
Evaluation of MASLD Fibrosis, FIB-4 and APRI Score in MASLD Combined with T2DM and MACCEs Receiving SGLT2 Inhibitors Treatment
Hua Liu, Yang-Min Hao, Sheng Jiang, et al.
International Journal of General Medicine (2024) Vol. Volume 17, pp. 2613-2625
Open Access | Times Cited: 1
XBP1-mediated transcriptional regulation of SLC5A1 in human epithelial cells in disease conditions
Yifei Sun, Yihan Zhang, Jifeng Zhang, et al.
Cell & Bioscience (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon‐like peptide 1
Nitin Deshmukh, M. S. Kalshetti, Mohan Patil, et al.
Clinical and Experimental Pharmacology and Physiology (2024) Vol. 51, Iss. 5
Closed Access | Times Cited: 1
Inflammation in Diabetic Kidney Disease: Focus on New Therapeutic Considerations
David J. Leehey, Xin Zhang
Medical Research Archives (2023) Vol. 11, Iss. 2
Open Access | Times Cited: 2
Progress in the Study of the Hepatoprotective Effect of SGLT2i on NAFLD Patients with T2DM
Fan Yang, Xiaoping Tan
Journal of Biosciences and Medicines (2024) Vol. 12, Iss. 01, pp. 115-125
Open Access
Elucidating the cardioprotective mechanisms of sodium-glucose cotransporter-2 inhibitors beyond glycemic control
Kexin Zhang, Chengxia Kan, Fang Han, et al.
World Journal of Diabetes (2024) Vol. 15, Iss. 2, pp. 137-141
Open Access
Influence of early use of sodium-glucose transport protein 2 inhibitors, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on the legacy effect of hyperglycemia
Siwei Deng, Houyu Zhao, Sanbao Chai, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access
The cellular and molecular mechanisms mediating the protective effects of sodium–glucose linked transporter 2 inhibitors against metabolic dysfunction‐associated fatty liver disease
Na Ao, Jian Du, Shi Jin, et al.
Diabetes Obesity and Metabolism (2024) Vol. 27, Iss. 2, pp. 457-467
Closed Access
Relationship between liver and cardiometabolic health in type 1 diabetes
Emir Tas, Bach-Mai Katherine Vu, Brenda Mendizábal, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access
Frequency and Factors Leading to Non-Adherence to SGLT-2 Inhibitors in Patients with Ischemic Heart Disease
A Saleem, Navedullah Khan, Gulzar Ali Buriro, et al.
Indus journal of bioscience research. (2024) Vol. 2, Iss. 2, pp. 1393-1399
Open Access
Time to Close the Gap Between Guidelines and the Reimbursement Policy for Diabetes Treatment in Turkey
Alper Tuna Güven
PharmacoEconomics (2023) Vol. 41, Iss. 8, pp. 843-844
Closed Access | Times Cited: 1
The Effect of Nanobubble Water Containing Cordyceps Extract and Withaferin A on Free Fatty Acid-Induced Lipid Accumulation in HepG2 Cells
Hanlin Han, Yixin Sun, Weixu Zhang, et al.
Nanomaterials (2023) Vol. 13, Iss. 15, pp. 2265-2265
Open Access | Times Cited: 1
Non-alcoholic fatty liver disease and risk of cardiovascular diseases: clinical association, pathophysiological mechanisms, and management
Rong Yang, Jian‐Gao Fan
Cardiology Plus (2023) Vol. 8, Iss. 4, pp. 217-226
Open Access | Times Cited: 1
Amlodipine alleviates renal ischemia/reperfusion injury in rats through Nrf2/Sestrin2/PGC-1α/TFAM Pathway
Hadi Shirzad, Seyed Amin Mousavinezhad, Mohammad Panji, et al.
BMC Pharmacology and Toxicology (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Utilizing type 2 diabetes medications outside glycemic parameters – where are we headed?
Natasha P. Malkani, Vanita R. Aroda
Current Opinion in Endocrinology Diabetes and Obesity (2022) Vol. 30, Iss. 1, pp. 1-6
Closed Access | Times Cited: 1
XBP1-mediated transcriptional regulation of SLC5A1 in human epithelial cells in disease conditions
Yifei Sun, Yihan Zhang, Jifeng Zhang, et al.
Research Square (Research Square) (2023)
Open Access
Slowing progression of chronic kidney disease with dapagliflozin
Peter Ellis
Journal of Kidney Care (2022) Vol. 7, Iss. 2, pp. 102-102
Closed Access
Previous Page - Page 2

Scroll to top